SCHEMBL4071976

SCHEMBL4071976

Oc1cccc(O)c1-n1ccnn1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 15/20 0.46
KEAP1 Q14145 1/20 0.46
CYP19A1 P11511 2/20 0.37
MAP3K5 Q99683 1/20 0.35
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CHRNB2 P17787 1/20 0.33
CYP2B6 P20813 1/20 0.33
MAOA P21397 1/20 0.33
CYP2C19 P33261 1/20 0.33
CHRNA4 P43681 1/20 0.33
HTR3A P46098 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17373622 0.89 NOTUM (0.42) NOTUMKEAP1HCRTR1HCRTR2CYP1A2
Hydrochloric Acid SCHEMBL23291644 0.87 NOTUM (0.41) NOTUMKEAP1HCRTR1HCRTR2CYP1A2
SCHEMBL170100 0.78 IDO1 (0.47) NOTUMKEAP1CYP1A2CYP2C9CHRNB2
SCHEMBL31245628 0.78 IDO1 (0.47) NOTUMKEAP1CYP1A2CYP2C9CHRNB2
SCHEMBL4071974 0.77 NOTUM (0.46) NOTUMKEAP1CYP19A1HCRTR1HCRTR2
Hydrochloric Acid SCHEMBL23291646 0.76 IDO1 (0.46) NOTUMKEAP1HCRTR1HCRTR2CYP1A2
SCHEMBL27613715 0.76 NOTUM (0.44) NOTUMKEAP1HCRTR1HCRTR2CYP1A2
SCHEMBL18284747 0.75 NOTUM (0.46) NOTUMKEAP1CYP19A1MAP3K5CYP1A2
SCHEMBL23291958 0.75 NOTUM (0.39) NOTUMKEAP1CYP19A1
Hydrochloric Acid SCHEMBL23292191 0.73 NOTUM (0.38) NOTUMKEAP1CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2118077-A2 TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY Synta Pharmaceuticals Corporation (US) 2009-11-18 EP disclosed
WO-2008097640-A2 TRIAZOLE COMPOUNDS THAT ARE USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS, SUCH AS CANCER SYNTA PHARMACEUTICALS CORP. (US) 2008-08-14 WO disclosed